Actually, several transcription-associated CDK inhibitors, including CDK7i (CT7001, SY-1365, SY-5609 and LY3405105), CDK8/19i (SEL120), and CDK9i (Alvocidib, TP-1287, BAY1251152 and AZD4573) have now progressed to Phase I/II clinical trials in various cancer types [8]. The gene discussed is CDK8; the disease is cancer.